Homepage Top Section2

The therapy claims to be the only oral inhibitor targeting the alternative complement pathway, specifically addressing what is believed to be the root cause of the disease. Usually

This collaboration leverages Porton Advanced’s cell and gene therapy manufacturing offerings and Artemis cell receptor as well as the E‑ALPHA antibody discovery platforms of Eureka. Through this partnership, Porton Advanced

The investment also comprises C$60m in funding from the Canadian federal government. Delpharm will manufacture sterile injectable drugs at the Boucherville site and bolster its local supply chain. The

This one-time-day cream claims to offer a non-steroidal alternative that is tailored for quick relief from itch and inflammation, with a suitability for long-term usage. Arcutis Canada general

This investigational medicine is stated to be the “first” ribonucleic acid (RNA) editing development candidate from the company’s Oligonucleotide Promoted Editing of RNA (OPERA) platform. Korro Bio chief

Versamune is the company’s new investigational MUC1-targeted immunotherapy candidate. The therapy is intended for individuals who have failed prior treatments. PDS submitted the application to the US regulator

This initiative is stated to be a part of the company’s Phase I contract development and manufacturing organisation (CDMO) growth strategy. In response to the growing need for

The collaboration aims to explore this WEE1 kinase inhibitor for treating human papillomavirus + (HPV+) and HPV- HNSCC with specific genomic markers. As per the agreement, Aprea will

This approval marks the first availability of the therapy in this region. The partnership between Vivus and its marketing partner PharmaAccess aims to equip healthcare providers in the